The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033
The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033, growing at a CAGR of 3.04% from 2024 to 2033 the surgery segment held the largest share of 77.35% in 2023.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8158
U.S. Actinic Keratosis Treatment Market by Overview
The U.S. Actinic Keratosis Treatment Market is characterized by several defining features. Actinic keratosis, a common precancerous skin condition, has gained prominence due to its potential to develop into skin cancer if left untreated. This condition primarily affects individuals over 40, aligning with the aging population trend in the U.S. The market’s landscape is further shaped by advancements in medical technology, leading to the emergence of various treatment options like topical therapies, cryotherapy, and photodynamic therapy, offering patients more effective and minimally invasive treatment choices. Additionally, increasing healthcare spending and favorable reimbursement policies contribute to ensuring widespread access to AK treatments across the nation. These factors collectively delineate a dynamic environment for AK treatment in the U.S., characterized by growing demand and evolving therapeutic strategies.
Key Takeaways:
- The surgery segment held the largest share of 77.35% in 2023 and is anticipated to continue leading during the projected period.
- However, the photodynamic therapy segment is projected to register the fastest growth rate over the forecast period.
- Based on topical/drugs segment, the nucleoside metabolic inhibitors dominated the market and is projected to hold a significant market share during the forecast period.
- The photo enhancers segment is anticipated to grow at the fastest rate throughout the forecast period.
- 5-fluorouracil was the leading segment in 2023 having a 32.28% share of AK drugs in the country.
U.S. Actinic Keratosis Treatment Market Growth
The increasing prevalence of actinic keratosis, the increased risk of developing skin cancer, and the surge in the geriatric population of the country are the major driving growth factors. For instance, according to a report published in JAMA Dermatology, actinic keratosis affects around three of every 10 older Medicare recipients. Moreover, the presence of potential investigational candidates in the pipeline and the rising R&D efforts from pharmaceutical companies to develop novel treatment approaches for actinic keratosis are likely to contribute to market expansion over the forecast period.
According to the American Academy of Dermatology Association, more than 40 million Americans develop AK each year and the overall prevalence rate of AK in the U.S. is estimated to be about 26.5% in males and 10.2% in females. Factors such as severe baldness, the high tendency of sunburn, and skin wrinkling may increase the predisposition to AK in the male population. In addition, it is the most common pre-cancerous dermatological condition, around 5-10% of actinic keratosis can develop into Squamous cell carcinoma. Thus, the increasing prevalence of AK is anticipated to increase the treatment rate in the country.
Currently, treatment approaches such as home-based treatments with topical preparations, cryotherapy, and PDT are commonly employed to treat actinic keratosis. Moreover, several novel agents are under development phases to reduce adverse events, which is expected to increase the adoption rate of treatment of actinic keratosis. For instance, according to the NIH, some of the novel drugs being investigated for AK are residuum, botulinic acid, paclitaxel, potassium desolate, potassium hydroxide, and celecoxib. These therapeutic drugs are directed toward personalized treatment for patients having AK lesions as well as symptoms of cutaneous SCC.
In addition, the ongoing efforts to develop next-generation therapeutics for various dermatological disorders including AK, basal cell carcinoma, and atypical moles are expected to offer lucrative growth opportunities for the market. For instance, in October 2022, the Skin Cancer Foundation granted USD 125,000 to researchers to manage dermatological applications. This funding is mainly intended to promote innovation for the early detection and treatment of skin diseases such as AK.
Furthermore, higher rates of actinic keratosis treatment and increasing novel medicines usage in the country along with favorable initiatives from non-profit organizations to prevent actinic keratosis is a growth rendering factor for the market. For instance, in June 2021, the American Academy of Dermatology published new recommendations for the treatment of AK with its new GRADE approach. Moreover, according to Almirall’s presentation, the prescription of Kisii in the U.S. AK topical market has increased by over 41,000 prescriptions since its launch.
However, most treatment options such as imiquimod, Solarize, and Feuded have lost their patent exclusivities in the U.S., leading to the penetration of generics in the market. Genericization is expected to lower the revenue generation capacity of the market, thereby impeding market growth. Moreover, a stringent regulatory framework related to the safety and efficacy of drugs is further anticipated to reduce market growth over the forecast period. For instance, in October 2020, Leo Pharma’s Picanto, a topical gel used to treat AK, was discontinued due to safety, efficacy, and quality reasons.
Immediate Delivery Available, Get Full Access@
https://www.novaoneadvisor.com/report/checkout/8158
What are the Importance of U.S. Actinic Keratosis Treatment Market?
- Prevalence of Actinic Keratosis: Actinic keratosis is a common skin condition, particularly in regions with high sun exposure like the United States. The market addresses the treatment needs of a large patient population.
- Risk of Progression to Skin Cancer: Actinic keratosis lesions have the potential to develop into invasive squamous cell carcinoma, a type of skin cancer. Treating actinic keratosis can prevent the progression to more serious conditions, reducing the burden of skin cancer.
- Quality of Life Improvement: Actinic keratosis lesions can be unsightly and may cause discomfort, itching, or pain. Effective treatment improves patients’ quality of life by relieving symptoms and restoring skin health.
- Medical Advancements: The U.S. market drives research and development efforts for innovative actinic keratosis treatments. Advancements in treatment modalities, such as topical medications, cryotherapy, photodynamic therapy, and surgical interventions, continually enhance patient outcomes.
- Economic Impact: Actinic keratosis treatment contributes to the economy through pharmaceutical sales, medical procedures, and healthcare services. A robust market stimulates investment in healthcare infrastructure and supports employment opportunities in various sectors.
- Public Health Initiatives: Addressing actinic keratosis aligns with public health initiatives aimed at preventing skin cancer and promoting skin health awareness. By investing in treatment options and education, the U.S. healthcare system demonstrates its commitment to proactive healthcare management.
- Long-term Health Benefits: Effective management of actinic keratosis reduces the need for more extensive and costly treatments for advanced skin cancers. Early intervention not only saves lives but also reduces healthcare expenditures associated with cancer treatment.
How is actinic keratosis diagnosed?
Healthcare providers can often diagnose an actinic keratosis by looking at and feeling the area on your skin. But sometimes an actinic keratosis can be hard to tell apart from skin cancer. Your healthcare provider might remove the area of skin to have it checked under a microscope. This is known as a skin biopsy.
U.S. Actinic Keratosis Treatment Market By Therapy Insights
The surgery segment held the largest share of 77.35% in 2023 and is anticipated to continue leading during the projected period. The higher demand for complete disease eradication and high penetration of cryotherapy procedures are fuelling segment uptake. However, the topical/drugs segment held the second largest share owing to the increasing trend for home-based treatment, lesser possibility of adverse effects, higher preference by medical professionals for topical treatments, and ongoing regulatory approvals. For instance, in December 2020, the U.S. FDA approved Kisii (trainline) for the topical treatment of actinic keratosis. Some of the common topical brands available for AK treatment are Carac, Feuded, Tolak, and Aldara among others.
However, the photodynamic therapy segment is projected to register the fastest growth rate over the forecast period. Factors such as the high site specificity of PDT, less incidence of adverse effects, the high adoption rate for long-term treatments, and great efficiency in patients with multiple skin lesions are responsible for the lucrative growth rate of the segment. In addition, significant clinical studies to enhance outcomes from PDT are other factors contributing to segment growth. For instance, in November 2022, Biofrontera Inc. announced the initiation of a phase-3 clinical study to evaluate the safety of BF-RhodoLED-XL and Ameluz in the management of AK.
U.S. Actinic Keratosis Treatment Market By Drug Class Insights
Based on topical/drugs segment, the nucleoside metabolic inhibitors dominated the market and is projected to hold a significant market share during the forecast period. The high growth rate of the segment is owing to the strong commercial performance of Fluroplex, Carac, and Efudex along with a higher demand for topical formulations to treat the initial stages of the condition. Moreover, the rising awareness regarding the diagnosis and treatment of disease has further fueled the segment’s growth.
The photoenhancers segment is anticipated to grow at the fastest rate throughout the forecast period. Factors including high efficacy, convenient handling, better skin rejuvenation, high healing rates, and lower recurrence rates of lesions are increasing the adoption of photoenhancers. In addition, the surge in demand for actinic keratosis treatment has also fueled segment uptake at a substantial rate. For instance, in 2021 an estimated 13.2 million actinic keratosis treatments were performed in the U.S.
Furthermore, several strategic initiatives undertaken by leading participants are another potential factor fueling segment growth. For instance, in March 2022, Biofrontera announced that the U.S. FDA added a patent for a novel RhodoLED XL lamp for performing PDT with its candidate Ameluz.
U.S. Actinic Keratosis Treatment Market By Product Insights
5-fluorouracil was the leading segment in 2023 having a 32.28% share of AK drugs in the country. Higher instances of reliable treatment and relatively lower chances of non-response to 5-FU are increasing the adoption of the drug for the treatment of actinic keratosis. In addition, the highest proven efficacy of up to 74% and significant therapeutic results are also expected to cater to the product demand. Moreover, owing to the high clearance rates it reduced the chance of developing squamous cell carcinoma.
The recent product approvals, strong commercial performance, satisfactory results in clinical trials, and fewer chances of remission are fueling the high growth rate of the tirbanibulin segment. Moreover, increasing awareness regarding the use of the product among the target population is further propelling the segment’s growth. For instance, in May 2022, Almirall partnered with Euromelanoma for raising awareness about skin conditions.
U.S. Actinic Keratosis Treatment Market By End-use Insights
The hospitals segment captured the largest revenue share of 31% in 2023. Factors such as treatment accessibility, high penetration of surgery, and increasing photodynamic therapy procedures performed in hospitals are supporting the segment share. Moreover, the increase in the number of physician-assisted therapies like cryotherapy, PDT, and laser therapy in moderate to severe cases of actinic keratosis is expected to fuel the segment growth over the forecast period.
Whereas, the homecare segment is likely to be the fastest-growing segment during the coming years. The growth of the segment is attributed to the rising adoption of topical products, patient convenience factors, availability of OTC products, and the increasing launch of products for topical use. The homecare segment has witnessed an increased demand owing to the rising availability of topical products including imiquimod, 5-FU, diclofenac, and trainline among others.
U.S. Actinic Keratosis Treatment Market Top Key Companies:
- Bausch Health Companies, Inc.
- LEO Pharma A/S
- Almirall, S.A
- Biofrontera AG
- GALDERMA
- Sun Pharmaceutical Industries Ltd
- Novartis AG
- Hill Dermaceuticals, Inc.
- 3M
- Viatris, Inc.
U.S. Actinic Keratosis Treatment Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Actinic Keratosis Treatment market.
By Therapy
- Topical/Drugs
- Surgery
- Cryotherapy
- Others
- Photodynamic Therapy
By Drug Class
- Nucleoside metabolic inhibitors
- Nonsteroidal anti-inflammatory drugs
- Immune response modifiers
- Photoenhancers
- Others
By Product
- 5-fluorouracil
- Carac
- Fluoroplex
- Actikerall
- Tolak
- Others
- Diclofenac
- Solaraze
- Voltaren
- Pennsaid
- Others
- Imiquimod
- Aldara
- Zyclara
- Others
- Tirbanibulin
- Capecitabine
- Xeloda
- Others
- Aminolevulinic acid
- Ameluz
- Levulan
- Porfimer sodium
- Others
- Gemzar
- Clolar
- Vidaza
- Metvix
- Others
By End-use
- Hospitals
- Private clinics
- Homecare
- Others
Order the 150+ Pages Detailed Report @ https://www.novaoneadvisor.com/report/checkout/8158
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com
